P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Hematology: Thalidomide maintenance in multiple myeloma.
TL;DR: Thalidomide is frequently used in patients with newly diagnosed and relapsed multiple myeloma, but its role as maintenance therapy following autologous stem-cell transplantation has been an area of uncertainty.
Journal ArticleDOI
An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma
Peter M. Voorhees,Robert L. Schlossman,Cristina Gasparetto,Jesus G. Berdeja,John C. Morris,Douglas A Jacobstein,Kenneth C. Anderson,Constantine S. Mitsiades,Jacob P. Laubach,Paul G. Richardson +9 more
TL;DR: A phase 1, multi-center, open-label, dose escalation trial was conducted to determine the maximum tolerated dose (MTD), assess toxicities, and evaluate response to treatment with monotherapy of PRLX 93936 in patients with relapsed or relapsed/refractory MM.
Journal ArticleDOI
Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)
Paul G. Richardson,Swethajit Biswas,Beata Holkova,Nicola Jackson,Thelma Netherway,Weichao Bao,Geraldine Ferron-Brady,Anne Yeakey,Chris Shelton,Rocio Montes de Oca,Chris Ahlers,Sonia Franco,Marc S. Ballas,Elaine M. Paul,Katarina Luptakova,Ira Gupta,Joanna Opalinska +16 more
TL;DR: Belantamab mafodotin monotherapy had a manageable safety profile and demonstrated rapid, deep and durable clinical response and significant progression free-survival (PFS) in patients with heavily pretreated MM.
Journal ArticleDOI
Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).
Jesús F. San-Miguel,Philippe Moreau,Sung-Soo Yoon,Meletios A. Dimopoulos,V. Hungria,Wiesław Wiktor Jędrzejczak,Ashraf el Ghandour,Paolo Corradini,Andreas Günther,Meral Beksac,Kwee Yong,Jae Hoon Lee,Sagar Lonial,Jian Hou,Hermann Einsele,Monika M Wroclawska-Swacha,Hans-Jochen Weber,Priscille M. Bourquelot,Paul G. Richardson +18 more
TL;DR: A blinded safety analysis is reported from PANORAMA 1, an international, randomized, double-blind, phase III study of PAN (or placebo) + BTZ + dexamethasone (Dex) in patients with multiple myeloma.
Book ChapterDOI
What We Can Deduce about Metabolism in the Moderate Halophile Chromohalobacter Salexigens from its Genomic Sequence
Laszlo N. Csonka,Kathleen O'Connor,Frank W. Larimer,Paul G. Richardson,Alla Lapidus,Adam D. Ewing,Bradley W. Goodner,Aharon Oren +7 more
TL;DR: This chapter presents a Brief overview of insights the authors gained into metabolism in c.